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ORIGINAL ARTICLE
Fentanyl, a synthetic opioid made soluble in a
citrate-binding form, is a regularly used agent for
intravenous (IV) general anesthesia (GA) induc-
tion. Fentanyl-induced cough (FIC) is undesired
during GA induction and is known to be associ-
ated with an increase in intracranial, intraocular
and intra-abdominal pressures. It is not always be-
nign and may be explosive, requiring immediate
intervention. Tweed and Dakin1 reported a case
of explosive and spasmodic coughing after periph-
eral IV injection of fentanyl that was severe enough
to produce periorbital petechiae; it was relieved
after GA induction. It is noteworthy that the inci-
dence of FIC is high, occurring in up to 65% of pa-
tients receiving a low dose of fentanyl (2.5 µg/kg,
IV) bolus injection.2 In our previous investigation,
we found that the incidence of FIC was lower in
light smokers; the possible mechanism of FIC
might be via C-fiber activation.3 Various attempts
have been made to reduce the incidence of FIC.2–8
One reported method is aerosol inhalation of the
corticosteroid beclomethasone 15 minutes prior
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to entering the operating room, which reduced the
incidence of FIC.6 However, the effect of IV steroid
administration on FIC has not yet been investi-
gated. In addition, dexamethasone (DEX 10 mg,
IV) has also been used to prevent postoperative
nausea and vomiting (PONV) when given before
GA induction.9 Therefore, the same treatment
(DEX 10 mg, IV) 5 minutes prior to fentanyl injec-
tion was used in the present study to evaluate its
effect on FIC.
Methods
Following approval by the institutional review
board, informed consent was obtained from all
patients included in this comparison study.
Eighty ASA (American Society of Anesthesiolo-
gists) I and II patients of either sex, aged 18–80
years and weighing 40–90 kg, scheduled for elec-
tive surgery under GA were included into the
DEX group. Exclusion criteria included history of
asthma, smoking, chronic cough, upper respira-
tory tract infection 2 weeks before the start of 
the study, or recent treatment with angiotensin-
converting enzyme inhibitors, bronchodilators,
or steroids. Patients for the reference, control,
group were selected from our previous study.3
After excluding smokers in patients receiving
fentanyl injection over 2 seconds in the previous
dataset, there were 108 cases who remained for
the present study.
Before induction of anesthesia, an IV cannula
on the dorsum of the patient’s hand was estab-
lished and connected to a T-connector for drug
injection to minimize the dilution effect during
fentanyl administration. In our hospital, all of
our patients are prepared initially with the same
IV set with a control bag for drug administration
and a 20-gauge IV catheter. All patients were
given fentanyl (100 µg for 40–69 kg and 150 µg
for 70–90 kg for clinical convenience) via the 
T-connector with a full run of IV fluid. Fentanyl
was injected over 2 seconds. Patients in the 
reference group received fentanyl injection with-
out any premedicant (from our previous study
database), and those in the DEX group received
DEX (10 mg, IV) bolus injection 5 minutes before
fentanyl injection. The number of coughs of each
patient was recorded for 30 seconds after fentanyl
injection, and the incidence and severity of cough
were recorded by another anesthesiologist. Anes-
thesia was induced immediately after cough cessa-
tion or 30 seconds following the end of fentanyl
injection.
Monitoring consisted of electrocardiography,
noninvasive blood pressure, pulse oximetry and
capnography. In our preliminary pilot study of
30 patients in a 3-minute observation period, we
found that all coughs occurred within 30 sec-
onds after fentanyl injection; therefore, we chose
30 seconds as the observation period for the current
study. Also, we had administered DEX 1 minute,
3 minutes and 5 minutes before fentanyl injection,
and found no obvious anti-FIC effect in most cases
when DEX was administered in the 1 minute and
3 minute groups. We therefore selected 5 minutes
in this trial. A 5-minute waiting period is also an
acceptable time in clinical practice.
Based on the number of coughs observed,
cough severity was graded as mild (1–2), moder-
ate (3–5), and severe (> 5). Heart rate (HR) and
blood pressure (BP) were recorded before drug
administration and 30 seconds after fentanyl in-
jection for patients who did not cough, or imme-
diately after cough stopped.
Statistical analysis
All data are reported as mean ± standard deviation
or percentages. The characteristics of the subjects
in the two groups and the number of coughs
among cough patients in the two groups were
evaluated by either Student’s t test or the Mann–
Whitney U test to compare the means. The χ2 test
or Fisher’s exact test was used to compare the dis-
tribution of gender, as well as the incidence and
severity of cough. Two-way analysis of variance
with one-way repeat was applied to evaluate the
changes in HR and BP before and after injection
between groups. All statistical analyses were two-
tailed. Statistical significance was accepted at the
5% probability level.
Results
Although the present study was not a standard
randomized controlled trial, the patient charac-
teristics in the two groups were comparable
(Table 1). There were more females than males
in each group, but there was no difference in
gender distribution between groups (p > 0.05).
The incidence of FIC in the reference group was
more than three times that of the DEX group
(21.3% vs. 6.3%; p=0.008) (Table 2). Although the
number of coughs among the patients with cough
was not significantly different between groups,
the incidence of moderate to severe cough was
higher in the reference group (11/23; 47.8%)
than in the DEX group (1/5; 20%).
There was no difference between groups in
the changes in systolic BP before and after drug
injection (data not shown) (groups and measures
interaction, p > 0.05). In the DEX group, the dif-
ferences in before and after diastolic BP (69.6 ±
10.6 mmHg vs. 68.7 ± 10.8 mmHg) and before
and after HR (69.3 ± 10.1 beats/min vs. 69.5 ± 10.3
beats/min) were insignificant (p > 0.05). However,
diastolic BP before (76.4 ± 11.9 mmHg) and after
(77.5 ± 13.1 mmHg) as well as HR before
(70.7 ± 10.2 beats/min) and after (72.6 ± 12.0
beats/min) fentanyl injection in the reference
group revealed a statistically significant interac-
tion of groups and measures, but was clinically
insignificant.
Discussion
FIC was effectively reduced by DEX (10 mg, IV)
pretreatment from 21.3% to 6.3% without signif-
icant hemodynamic change, and FIC was found
to be not age-related. Historical control was used
as an alternative for various reasons. Firstly, we
had already studied a reference group with a 
2-second fentanyl injection time, which could
serve as a “de facto” control group. It was possible
to match the physical (hospital, operating theater),
organizational (clinical protocol) and patient 
selection (for gender, age, anthropometry, elective
surgery, past medical history, inclusion–exclusion
criteria) to a high degree. Besides, the principal
outcome measure, cough incidence and severity,
was an objective indicator not involving bias.
Secondly, for ethical reasons related to the value of
the intervention with DEX premedicant, a re-run
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Table 1. Patient characteristics*
DEX group (n = 80) Reference group (n = 108) p
Age (yr) 49.9 ± 18.0 45.7 ± 17.4 0.103
Sex (M/F) 35/45 50/58 0.843
Weight (kg) 62.0 ± 10.7 61.6 ± 11.9 0.830
Height (cm) 162 ± 9.71 163 ± 8.37 0.473
BMI (kg/m2) 23.6 ± 3.56 23.1 ± 3.38 0.324
*Data are presented as mean ± standard deviation or n. DEX = dexamethasone; BMI = body mass index.
Table 2. Incidence and severity of cough after fentanyl injection
Severity of cough among 
Group Incidence (%)
Number of coughs among those those who coughed‡ (%)
who coughed (mean ± SD)
Mild Moderate Severe
DEX (n = 80) 6.3* 2.20 ± 1.64† 80.0 20.0 0.0
Reference (n = 108) 21.3 2.96 ± 2.21 52.2 34.8 13.0
*p = 0.008 vs. reference group; †p = 0.478 vs. reference group; ‡p = 0.355, mild vs. moderate to severe, Fisher’s exact test. SD = standard
deviation; severity of cough = number of coughs observed in 30 seconds: mild (1–2), moderate (3–5), and severe (> 5).
of non-intervention was not acceptable. Although
a fentanyl injection time of 2 seconds allowed
more FIC than a longer injection time period
(e.g. 30 seconds) in our previous study,3 the per-
sistence in the practice of this suboptimal clinical
protocol encouraged the quest for an alternative
solution. In so doing, we were able to avoid the
unnecessary repeat of a potentially non-DEX-
protected arm in the present study. Thirdly, the
proposition which was testable by our design was
that IV DEX would decrease FIC. Ultimately, we
contend that, although not absolute proof, it is our
collective studies which argue for best practice
for fentanyl use to be preceded by parenteral DEX
in addition to slowing the fentanyl injection time.
Because this was a non-randomized trial, there
must be some limitation in the treatment group
including subjective feeling of patients during the
waiting period between DEX and fentanyl injec-
tion no matter whether it caused bias. No active
complaints were reported by patients and no sig-
nificant hemodynamic changes were noted during
the waiting period. Therefore, the influence of the
bias, if any, is likely to have been minimal.
Previous clinical studies2–8,10 on FIC via a 
peripheral line revealed variable incidences and
many measures have been reported to reduce the
incidence of FIC2–8 (Table 3). Lidocaine was re-
ported to effectively inhibit FIC in clinical anesthe-
sia practice,2,4,5 but justification of pretreatment
with lidocaine was questioned because lidocaine
may have arrhythmogenic effect, and its vasodila-
tory effect could even augment the cardiovascular
depression of induction agents.11 Administration
of ephedrine (5 mg, IV) 1 minute prior to fentanyl
injection2 seems to be promising for attenuating
FIC, but it is relatively contraindicated in patients
with coronary artery disease or severe hyperten-
sion. Moreover, inhalation of β2-agonist, steroid,
and mast cell stabilizer (sodium chromoglycate)
aerosol reduced FIC,6,7 but they are not feasible
as patients need to wait 15 minutes before fentanyl
injection and anesthesia induction. Intramuscu-
lar (IM) morphine (0.2 mg/kg) injection 1 hour
before fentanyl (1.5µg/kg, IV) injection was found
to effectively attenuate the incidence of FIC,8
but it was also not clinically applicable due to
the relatively long time interval and delayed GA
induction.
Curiously, the centrally-acting antitussive
agent, fentanyl, causes frequent cough in clinical
anesthesia practice. One of the possible explana-
tions might be related to the citrate salt in fentanyl
citrate,4 which was found to stimulate C-fiber in
the lower respiratory tract and induce cough.12 The
C-fiber mechanism of FIC was suggested by our
previous clinical investigation3 and Bohrer et al’s
report.10 Bohrer and coworkers reported that a
higher dose of fentanyl (7 µg/kg, IV) bolus injec-
tion paradoxically yielded a low incidence (2.7%)
of FIC (Table 3), and we suggest that, at such a
dose, the centrally-acting antitussive effect of fen-
tanyl sufficiently overcomes the effect of citrate
stimulation on the lower respiratory tract. DEX
was reported to be a mast cell stabilizer in a
human mast cell line,13 and it only ameliorated
tachykinin-mediated but not acetylcholine-
mediated bronchoconstriction in guinea pigs.14
Tachykinin, released after airway C-fiber activation,
can excite rapidly adapting receptors either directly
via facilitating smooth muscle contraction15 or
indirectly via inducing histamine release from
airway mast cells.16 Taken together, DEX might
suppress FIC via inhibiting tachykinin-mediated
hyperreactivity of airways, but not directly on the
bronchoconstriction-mediated cough receptor
activation in the respiratory tract. However, most
studies on citric acid-induced cough used a guinea
pig model because they express a higher density of
tachykinin-containing airway C-fibers than human
beings.17 Evidence of interaction between citric
acid and tachykinin in humans is lacking. Whether
DEX reduces FIC by suppressing tachykinin as we
propose needs to be further investigated.
Corticosteroid has been used to inhibit
bronchial hyperirritability, mucosal edema and the
inflammatory response of airways.18 Moreover, a
single IV bolus of low-dose DEX prior to surgery
has also been proven to be beneficial in many
other aspects. DEX is a well-established antiemetic
that may antagonize prostaglandin and enhance
endorphin release that elevates mood, improves
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wellbeing, and stimulates appetite.19 A prophy-
lactic dose of DEX (8–10 mg, IV) was demon-
strated to prevent PONV,9 and it was particularly
effective when administered before the induction
of anesthesia.20 Coloma and coworkers reported
that DEX (4 mg) pretreatment shortened the time
to “home readiness” and facilitated discharge in
patients who had received anorectal surgery.21
In uncomplicated laparoscopic cholecystectomy,
8 mg of DEX reduced postoperative pain and 
inflammatory condition with a lower C-reactive
protein level.22 Moreover, steroids have been
used to reduce postoperative edema in many
kinds of surgery; 10 mg of DEX was found to 
reduce wound swelling and make extubation ear-
lier following transoral neurosurgical surgery.23
Although corticosteroid-related side effects such
as wound infection and adrenal suppression were
occasionally observed in long-term use patients,
they were not noted after a low-dose DEX bolus.9
To obtain the most benefits described above,
DEX (10 mg, IV) bolus injection 5 minutes prior
to fentanyl injection seemed to be feasible to 
reduce FIC. However, the physiologic dose of
DEX in adults is 0.5 mg/day, and 10 mg DEX
equals 20 times the physiologic dose. Although
no immediate impact was found on normal
healthy adults, such a high dose might result 
in adverse effects in some diabetic and hyperten-
sive patients and, therefore, should be used with
caution.
In conclusion, DEX (10 mg, IV) bolus injection
5 minutes prior to fentanyl administration is a
feasible and convenient way to reduce the inci-
dence of FIC. Moreover, DEX pretreatment is
known to attenuate PONV9,20 and provide better
postoperative pain relief.22 Thus, DEX (10 mg, IV)
can reduce the incidence of FIC and may also be
beneficial otherwise.
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